南京医药：与白云山、广药二期基金签订战略投资协议

Core Viewpoint - Nanjing Pharmaceutical (600713) has signed a strategic investment agreement with Baiyunshan (600332) and Guangyao Phase II Fund, where Baiyunshan's subsidiary plans to acquire 11.04% of the company's shares from its second-largest shareholder, Alliance Healthcare Asia Pacific Limited [1] Group 1 - The strategic investment aims to establish a long-term stable partnership characterized by "patient capital" between Nanjing Pharmaceutical and Baiyunshan [1] - The collaboration will focus on capital aspects, distribution channels for proprietary industrial products, and deep cooperation in traditional Chinese medicine [1] - The parties involved will explore various forms of collaboration, including but not limited to establishing joint ventures, strategic investments, and equity investment funds at appropriate times [1]